January 30, 2024
Abdera Therapeutics Expands Management Team and Board of Directors
Read
April 20, 2023
Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
Read